Estela Rodriguez, Associate Director of Community Outreach in Thoracic Oncology at the University of Miami’s Sylvester Comprehensive Cancer Center, shared on X:
“It’s been a weird week. Planes grounded, Outlook down, and now FDA declines to approve Summit Therapeutics ivonescimab for EGFR-mutant lung cancer after osimertinib resistance (HARMONi trial).
Despite a meaningful PFS benefit, lack of demonstrated OS benefit was the deciding factor – a challenging standard, particularly when other cancer drugs have been approved with similar PFS/OS discrepancies in this space.”
You can also read: FDA Declines Ivonescimab Plus Chemotherapy Approval in EGFR-Mutated NSCLC Following HARMONi Results.
